CD38 expression on tumor cells was reported to rise in murine and human origins in response to PD-L1 antibody therapy, which led to dysfunction of tumor-infiltrating CD8 T cells due to increasing adenosine production (21). This evidence concerns the gene CD38 and neoplasm.